Okun The New England Journal of Medicines recent publication of a randomized study of a GLP-1 agonist originally designed for diabetes, but applied to Parkinson's disease, has led to a flurry of excitement and to a mountain of questions
It prevents liver damage by shielding the liver from dangerous chemicals
The drug was in medications targeted at consumers suffering all manner of ills, from colds to arthritis aches to insomnia caused by pain
For many patients, that makes long-term planning just as important as the weight loss itself
combination studies with semaglutide in rodent obesity models References (Cagrilintide): Carvas AO, Leuthardt A, Kulka P, et al
Foods are designed now to make us want to eat more of them, and that leads to increased calorie intake, which leads to gaining weight